Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole

被引:30
|
作者
Abed, Mohammed N. [1 ,2 ]
Alassaf, Fawaz A. [1 ,3 ]
Jasim, Mahmood H. M. [1 ,2 ]
Alfahad, Mohanad [1 ,4 ]
Qazzaz, Mohannad E. [1 ,5 ]
机构
[1] Univ Mosul, Coll Pharm, Mosul, Iraq
[2] Univ Mosul, Dept Pharmaceut Chem, Mosul, Iraq
[3] Univ Mosul, Dept Pharmacol & Toxicol, Mosul, Iraq
[4] Univ Mosul, Dept Pharmaceut, Mosul, Iraq
[5] Univ Mosul, Dept Pharmacognosy & Med Plants, Mosul, Iraq
关键词
Peptic ulcer; Proton pump inhibitors; Oxidative damage; Free radicals; alpha; alpha-Diphenyl-beta-picrylhydrazyl; Antioxidants; HELICOBACTER-PYLORI INFECTION; IN-VITRO ANTIOXIDANT; OXIDATIVE STRESS;
D O I
10.1159/000506232
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Peptic lesions usually develop when there is an imbalance between aggressive drivers and gastro-protective mediators that guard the lining of the gastrointestinal tract. The most crucial of these mediators are antioxidants, whose loss may predispose to oxidative stress, which is believed to be the main aggravator of several diseases including peptic ulcer. Proton pump inhibitors (PPIs) are drugs that are highly effective and widely used for therapeutic management of peptic disorders through inhibition of gastric acid secretion. In spite of this, oxidative damage may continue to be a major issue that can predispose to future lesions. Objective: The present study is designed to explore the possible antioxidant capability of different PPIs, including omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole, in an aim to suggest an agent that, in addition to its acid-suppression properties, can provide antioxidant profit. Methods: The antioxidant activity of different PPIs was evaluated calorimetrically to test the ability of each drug to quench oxygen free radical, using the well-known stable free radical alpha,alpha-diphenyl-beta-picrylhydrazyl (DPPH), and compared to ascorbic acid (AA; vitamin C). The measurements were performed using a spectrophotometer at 517 nm. Results: All the studied drugs reduced DPPH, but to different extents. However, omeprazole and esomeprazole showed the highest ability to scavenge free radicals (50% inhibitory concentrations [IC(50)s] of the percentage for free radical scavenging activity are 18.7 +/- 5.7 and 18.7 +/- 5.7, respectively, and the AA equivalents are 83,772 +/- 11,887 and 81,732 +/- 8,523 mg AA/100 g, respectively). Conversely, lansoprazole, pantoprazole, and rabeprazole might be having no role in this story (IC(50)s of the percentage for free radical scavenging activity are 49.3 +/- 3.1, 49 +/- 9.4, and 40.7 +/- 7.2, respectively, and the AA equivalents are 30,458 +/- 3,884, 32,222 +/- 10,377, and 37,876 +/- 8,816 mg AA/100 g, respectively). Conclusion: Thus, omeprazole and esomeprazole may confer a significant dual action in gastrointestinal protection by providing potent antioxidant properties in addition to their major role as acid-suppression agents. However, further studies are essential to elucidate the mechanism behind the difference between the drugs of the same class. (C) 2020 S. Karger AG, Basel
引用
收藏
页码:645 / 651
页数:7
相关论文
共 50 条
  • [31] Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms
    Kerstin Röhss
    Tore Lind
    Clive Wilder-Smith
    European Journal of Clinical Pharmacology, 2004, 60 : 531 - 539
  • [32] Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms
    Röhss, K
    Lind, T
    Wilder-Smith, C
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 60 (08) : 531 - 539
  • [33] Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: A comparison with other proton pump inhibitors
    Masubuchi, N
    Hakusui, H
    Okazaki, O
    DRUG METABOLISM AND DISPOSITION, 1997, 25 (05) : 584 - 589
  • [34] Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole
    Hartmann, M
    Theiss, U
    Huber, R
    Luhmann, R
    Bliesath, H
    Wurst, W
    Lucker, PW
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 (03) : 359 - 366
  • [35] Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis - Comparison of on-demand esomeprazole with conventional omeprazole strategies
    Wahlqvist, P
    Junghard, O
    Higgins, A
    Green, J
    PHARMACOECONOMICS, 2002, 20 (04) : 267 - 277
  • [36] Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitors
    Miner, P. B., Jr.
    McKean, L. A.
    Gibb, R. D.
    Erasala, G. N.
    Ramsey, D. L.
    McRorie, J. W.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (08) : 846 - 851
  • [37] Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose The PACA (Proton Pump Inhibitors And Clopidogrel Association) Prospective Randomized Study
    Cuisset, Thomas
    Frere, Corinne
    Quilici, Jacques
    Poyet, Raphael
    Gaborit, Benedicte
    Bali, Laurent
    Brissy, Olivier
    Morange, Pierre-Emmanuel
    Alessi, Marie-Christine
    Bonnet, Jean-Louis
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (13) : 1149 - 1153
  • [38] Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life:: effects on intragastric pH and comparison with esomeprazole in healthy volunteers
    Galmiche, JP
    Des Varannes, SB
    Ducrotté, P
    Sacher-Huvelin, S
    Vavasseur, F
    Taccoen, A
    Fiorentini, P
    Homerin, M
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (06) : 655 - 662
  • [39] A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism
    Miyoshi, M
    Mizuno, M
    Ishiki, K
    Nagahara, Y
    Maga, T
    Torigoe, T
    Nasu, J
    Okada, H
    Yokota, K
    Oguma, K
    Tsuji, T
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 16 (07) : 723 - 728
  • [40] Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxicillin, and clarithromycin.
    Dojo, M
    Azuma, T
    Ohtani, M
    Muramatsu, A
    Suto, H
    Ito, Y
    Kuriyama, M
    GASTROENTEROLOGY, 2001, 120 (05) : A582 - A582